Rishindra M. Reddy, M.D., was born and raised in Michigan. He earned his undergraduate and medical degrees at Northwestern University, and completed his general surgery residency at Washington University-Barnes Jewish Hospital in St. Louis, Missouri. His spent two years during his residency, as a Clinical Research Fellow at the National Cancer Institute in Bethesda, Maryland. He completed his Thoracic Surgery residency at the University of Washington and was a visiting fellow at Memorial Sloan Kettering Cancer Center in New York.
Dr. Reddy is currently working with Dr. Beer, of Thoracic Oncology, evaluating novel molecular pathways, currently Chk1, in lung cancer. He is also developing primary tumor xenografts of both lung and esophageal cancer. His goal is to develop this model with a translational goal of bringing new therapeutics to the clinic and improving lung and esophageal cancer outcomes. Other academic interests include teaching of residents and medical students and his participation at a national level to increase recruitment into cardiothoracic surgery.
Nguyen DM, Chen GA, Reddy RM, Tsai WS, Schrump WD, Cole GW Jr, Schrump DS. Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway. J Thorac Cardiovasc Surg. 2004;127:365-75.
Reddy RM, Tsai WS, Ziauddin FM, Zuo JT, Cole GW, Jr, Maxihmer JB, Fang B, Schrump DS, Nguyen DM. Cisplatin enhances apoptosis induced by a tumor-selective adenovirus expressing TRAIL. J Thorac Cardiovasc Surg. 2004; 128(6):883-91.
Maxhimer JB, Reddy RM, Zuo JT, Cole GW,Jr, Schrump DS, Nguyen DM. Profound induction of apoptosis of lung and esophageal cancer cells by the histone deacetylase inhibitor Trichostatin A/protein kinase C inhibitor Calphostin C combination. J Thorac Cardiovasc Surg. 2005;129(1):53-63.